InfuSystem Holdings (1TZ) AI Stock Analysis

InfuSystem Holdings

(Frankfurt:1TZ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Oncology Scale and Market PositionGrowth in the core Oncology business, combined with relationships across 18 of the top 20 U.S. hospital systems, supports durable customer reach and treatment volumes. This scale can reinforce retention, utilization, reimbursement capabilities, and the company’s position in outpatient infusion services.

Negative Factors

GE Contract Revenue ReductionThe GE Healthcare contract restructuring creates a material recurring revenue reset that will weigh on reported growth over the next several quarters. Although the change improves margins through lower direct costs, replacing the lost revenue remains an execution requirement for sustained expansion.

InfuSystem Holdings (1TZ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 280.24M
Dividend Yield: ―
Average Volume (3M): 1,537
Price to Earnings (P/E): 33.5
Beta (1Y): 0.88
Revenue Growth: -4.45%
EPS Growth: 67.27%
Country: Germany
Employees: 467
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Dur...

InfuSystem Holdings Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:59.24%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call presents a largely positive operational and financial picture: record quarterly revenue, double-digit growth in Wound Care, expansion of margins (consolidated and in Device Solutions), adjusted EBITDA growth and strong cash/liquidity metrics. Offsetting items include a material near-term revenue reduction from the GE contract restructuring (partly margin-accretive), a meaningful decline in Device Solutions revenue and equipment sales, pressure on Patient Services margins due to product mix and higher operating expenses, and continued ERP-related spend during stabilization. On balance, the improvements in revenue, EBITDA, margins, product-market expansion (lymphedema/compression devices), and conservative leverage outweigh the headwinds.

Positive Updates

Record Quarterly Revenue

Revenue of $36.9 million in Q2 2026, a new quarterly record; up $1.0 million or 2.6% year-over-year on a GAAP basis and up 7.5% on a non-GAAP pro forma basis (excluding GE Healthcare contract restructuring).

Negative Updates

GE Healthcare Contract Restructuring Reduced Revenue

Restructuring of the biomedical services contract with GE Healthcare reduced Q2 revenue by $1.6 million and is expected to lower annual revenue by approximately $7.1 million — a material near-term revenue headwind, albeit improving margins through reduced direct contract expenses.

Company Guidance

Management guided that, after adjusting for the $7.1 million annual revenue reduction from the GE Healthcare contract restructuring, it expects pro forma annual revenue growth of 6–8% for 2026 and to maintain adjusted EBITDA margins in the low- to mid-20% range (consistent with a longer‑term 22–25% target), inclusive of IT upgrade costs, with management suggesting the 22–25% range is achievable within roughly 2–3 years; for context, Q2 revenue was $36.9M (GAAP +2.6% YoY; pro forma +7.5%), adjusted EBITDA was $8.6M (23.4% margin), Oncology exceeded $20M (up 6.4%), Wound Care grew $2.1M (154%), Device Solutions revenue was $12.1M (down 16.1%), consolidated gross profit was $21.4M (gross margin 58% vs 55.2% LY), net income was $3.2M ($0.15/diluted), operating cash flow for the first six months was $7.7M, investments in rental equipment were $6.5M, share repurchases were $4.4M, available liquidity was $55.2M, and net debt was $19.5M (0.61x TTM adjusted EBITDA).

InfuSystem Holdings Risk Analysis

InfuSystem Holdings disclosed 14 risk factors in its most recent earnings report. InfuSystem Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

InfuSystem Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1TZ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	75Outperform	$216.06M	20.37	8.78%	1.82%	-9.62%	―
OSUR	52Neutral	$271.74M	-5.71	-14.73%	―	-18.86%	-0.63%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KRMD	48Neutral	$138.05M	-76.28	-10.63%	―	22.41%	60.02%
SMTI	46Neutral	$301.64M	-8.83	-473.55%	―	12.93%	-219.19%

* Healthcare Sector Average

Performance Comparison

DE:1TZ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1TZ	InfuSystem Holdings, Inc.	12.50	4.05	47.93%
OSUR	Orasure	3.94	1.27	47.57%
UTMD	Utah Medical Products	68.08	10.69	18.63%
KRMD	Repro-Med Systems, Inc.	2.99	-0.85	-22.14%
SMTI	Sanara MedTech	32.83	3.84	13.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InfuSystem Holdings AI Stock Analysis